CTKB vs BIO

For growth investors, Bio-Rad Laboratories, Inc.

(BIO) is the stronger pick with 0. 7% revenue growth year-over-year, versus 0. 5% for Cytek Biosciences, Inc. (CTKB). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 1x trailing P/E (27. 4x forward), making it the more compelling value choice. Analysts rate Cytek Biosciences, Inc. (CTKB) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Bio-Rad Laboratories, Inc.

(BIO) delivered a total return of -57. 9%, compared to -75. 4% for Cytek Biosciences, Inc. (CTKB). Over 10 years, the gap is even starker: BIO returned +79. 3% versus CTKB's -75. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.

(BIO) is the lower-risk stock at 0. 91β versus Cytek Biosciences, Inc. 's 1. 66β — meaning CTKB is approximately 82% more volatile than BIO relative to the S&P 500. On balance sheet safety, Cytek Biosciences, Inc. (CTKB) carries a lower debt/equity ratio of 7% versus 21% for Bio-Rad Laboratories, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bio-Rad Laboratories, Inc.

(BIO) is pulling ahead at 0. 7% versus 0. 5% for Cytek Biosciences, Inc. (CTKB). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to -1028. 0% for Cytek Biosciences, Inc.. Over a 3-year CAGR, CTKB leads at 7. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus -33. 0% for Cytek Biosciences, Inc. — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIO leads at 10. 5% versus -20. 0% for CTKB. At the gross margin level — before operating expenses — BIO leads at 52. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CTKB: 30.

2% to $6. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Bio-Rad Laboratories, Inc.

(BIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91)). Cytek Biosciences, Inc. (CTKB) carries a higher beta of 1. 66 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BIO: +79. 3%, CTKB: -75. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CTKB is a small-cap quality compounder stock; BIO is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.